Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Eli Lilly's strong Q2 market cap growth driven by diabetes drug Mounjaro - GlobalData

Published 08/21/2023, 11:04 PM
© Reuters.
LLY
-
MRK
-
PFE
-
ABBV
-

According to data analytics firm GlobalData, the top 20 global biopharmaceutical companies reported a 2.3% market cap growth in Q2 2023.

Despite continued inflationary pressures, the second quarter "yielded promising outcomes for the leading 20 biopharmaceutical giants," said the firm.

GlobalData analysts said Eli Lilly & Company (NYSE:LLY) witnessed the largest market capitalization growth of 36.1% over Q2 2023. It moved up to first position in the list, "displacing Johnson & Johnson from its top spot for the first time even though it reported a 6.8% increase in market capitalization."

LLY's strong market capitalization growth was said to have been driven by its diabetes drug Mounjaro.

Meanwhile, Merck (NYSE:MRK) rose to third position with an 8.4% market capitalization increase due to its $10.8 billion acquisition of Prometheus Biosciences.

"This strengthens Merck & Co’s immunology pipeline with the addition of PRA023 – a monoclonal antibody drug currently being evaluated in ulcerative colitis, Crohn’s disease, and systemic sclerosis – which is forecasted to achieve global sales of $2.1 billion by 2029," GlobalData stated.

Despite the rise in some names, more than half of the top 20 reported a decline in their market capitalization over Q2 2023. For example, AbbVie (NYSE:ABBV) declined by -15.5%, while Pfizer's (NYSE:PFE) fell by -10.1%.

The analysts added that biopharmaceutical companies such as AbbVie are "starting to experience the consequences of biosimilar competition."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.